Form 8-K - Current report:
SEC Accession No. 0001193125-22-294309
Filing Date
2022-11-29
Accepted
2022-11-29 16:11:36
Documents
13
Period of Report
2022-11-29
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d191955d8k.htm   iXBRL 8-K 27715
2 EX-99.1 d191955dex991.htm EX-99.1 17718
  Complete submission text file 0001193125-22-294309.txt   177454

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sana-20221129.xsd EX-101.SCH 2830
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sana-20221129_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sana-20221129_pre.xml EX-101.PRE 11694
7 EXTRACTED XBRL INSTANCE DOCUMENT d191955d8k_htm.xml XML 3473
Mailing Address 188 EAST BLAINE STREET, SUITE 400 SEATTLE WA 98102
Business Address 188 EAST BLAINE STREET, SUITE 400 SEATTLE WA 98102 (206) 701-7914
Sana Biotechnology, Inc. (Filer) CIK: 0001770121 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39941 | Film No.: 221432904
SIC: 2836 Biological Products, (No Diagnostic Substances)